文献速递乳腺癌

他拉唑帕利治疗晚期乳腺癌及胚系BRCA1/2突变患者的生活质量:ABRAZO 2期试验患者报告结局

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
PubMed 文献 · Eur J Cancer · 2018-10-22

ABRAZO 2期试验评估他拉唑帕利(1 mg/日)在晚期乳腺癌患者中的患者报告结局。患者为铂类治疗缓解后(队列1,n=49)或≥3种不含铂的细胞毒方案后(队列2,n=35)。两队列总体健康状况/生活质量自基线维持,但队列1角色功能与队列2呼吸困难症状出现显著且有临床意义的恶化。

要点

  • 两队列总体健康状况/生活质量自基线维持。
  • 队列1角色功能、队列2呼吸困难症状总体显著恶化。
  • 两队列乳腺症状、手臂症状及未来展望显著改善。

核心结论

  • 尽管队列1角色功能和队列2呼吸困难症状出现显著且有临床意义的总体恶化,两队列患者乳腺症状、手臂症状和未来展望显著改善,且总体健康状况/生活质量自基线维持。

研究设计与样本

  • ABRAZO为两队列、两阶段2期研究,评估他拉唑帕利(1 mg/日)在晚期乳腺癌患者中的患者报告结局。
  • 队列1为铂类治疗缓解后患者(n=49),队列2为≥3种不含铂的细胞毒方案后患者(n=35)。
  • 患者报告结局采用EORTC QLQ-C30及其乳腺癌模块QLQ-BR23评估,基线为第1天,前24周每6周评估,之后每12周直至进展。

主要发现

  • 两队列总体健康状况/生活质量在所有时间点自基线维持。
  • 队列1和队列2总体健康状况/生活质量至恶化中位时间分别为2.8个月(95%CI 2.1, 3.0)和5.5个月(95%CI 4.2, 5.7)。
  • 队列1和队列2所有QLQ-C30功能量表至恶化中位时间范围分别为2.1-3.1个月和4.2-5.6个月。
  • 队列1和队列2所有QLQ-BR23症状量表至恶化中位时间范围分别为2.6-4.0个月和4.2-5.6个月。
  • 两队列总体健康状况/生活质量自基线估计总体变化无统计学显著差异:队列1为-2.6(95%CI -7.8, 2.5),队列2为1.2(95%CI -5.5, 8.0)。

临床怎么用

  • 他拉唑帕利治疗期间应关注角色功能和呼吸困难症状的恶化,并给予相应支持。
  • 乳腺症状、手臂症状及未来展望的改善可作为患者报告结局的获益参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Talazoparib (1 mg/day) exhibited promising efficacy and safety in patients with advanced breast cancer during ABRAZO (NCT02034916); this study evaluated patient-reported outcomes (PROs). PATIENTS AND METHODS: ABRAZO is a two-cohort, two-stage, phase 2 study of talazoparib in patients with advanced breast cancer after a response to prior platinum-based therapy (cohort 1 [C1], n = 49) or ≥3 platinum-free cytotoxic-based regimens (cohort 2 [C2], n = 35). PROs were assessed on day 1 (baseline), every 6 weeks for an initial 24 weeks, and every 12 weeks thereafter until progression, using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) and its breast cancer module, QLQ-BR23. RESULTS: Global health status/quality of life (GHS/QoL) was maintained from baseline across all time points for both C1 and C2. For C1 and C2, median time to deterioration (TTD) of GHS/QoL (95% confidence interval [CI]) was 2.8 (2.1, 3.0) and 5.5 (4.2, 5.7) months, respectively. Median TTD for all QLQ-C30 functional scales for C1 and C2 ranged 2.1-3.1 months and 4.2-5.6 months, respectively; median TTD for all QLQ-BR23 symptom scales ranged 2.6-4.0 months and 4.2-5.6 months, respectively. There were no statistically significant differences in estimated overall change from baseline in the GHS/QoL scale for both cohorts (C1: -2.6 [95% CI, -7.8, 2.5]; C2: 1.2 [95% CI, -5.5, 8.0]). Significant overall improvements in the breast symptoms and arm symptoms and the future perspective of patients in C1 and C2 were observed, despite the statistically significant and clinically meaningful overall deterioration among patients regarding their role functioning (in C1) and dyspnoea symptoms (in C2). CONCLUSION: Despite the statistically significant and clinically meaningful overall deterioration among patients regarding their role functioning (in C1) and dyspnoea symptoms (in C2), patients in both C1 and C2 reported significant overall improvements in their breast symptoms, arm symptoms and future perspective, and their GHS/QoL was maintained from baseline.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hurvitz SA, Quek RGW, Turner NC, et al. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. Eur J Cancer. 2018. PMID: 30359909. doi:10.1016/j.ejca.2018.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。